首页> 外文期刊>Recent patents on regenerative medicine. >Recent patents in cell therapy for amyotrophic lateral sclerosis
【24h】

Recent patents in cell therapy for amyotrophic lateral sclerosis

机译:肌萎缩性侧索硬化的细胞疗法的最新专利

获取原文
获取原文并翻译 | 示例
           

摘要

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron degeneration in the brain and spinal cord. Reliable treatment options for this disease are limited due to complexity and multifactorial causes of motor neuron damage. Cell therapy might be a promising treatment for ALS. Numerous preclinical studies have validated the feasibility of cell therapy using various cell types and routes of administration. These cell therapy approaches largely take one of two distinct therapeutic strategies: neuroprotection or motor neuron replacement. Despite some promising results, the success of cell therapy in ALS might rely on a combinative strategy that exploits the benefits of both neuronal cell protection and replacement. Although, ongoing clinical trials provide promising results in cell therapy for treatment of ALS patients, some challenges still facing potential cell therapy development. In this review, current cell products and patent technology related to cell therapeutic strategies are discussed. A detailed discussion of this topic might offer vital insight into the future and viability of cell therapy for ALS.
机译:肌萎缩性侧索硬化症(ALS)是一种神经退行性疾病,其特征在于大脑和脊髓中进行性运动神经元变性。由于运动神经元损伤的复杂性和多因素原因,限制了对该疾病的可靠治疗选择。细胞疗法可能是ALS的有前途的治疗方法。许多临床前研究已经证实了使用各种细胞类型和给药途径进行细胞疗法的可行性。这些细胞疗法主要采用两种不同的治疗策略之一:神经保护或运动神经元替代。尽管取得了一些令人鼓舞的结果,但ALS中细胞治疗的成功可能依赖于一种结合策略,该策略充分利用了神经元细胞保护和置换的优势。尽管正在进行的临床试验在治疗ALS患者的细胞疗法中提供了可喜的结果,但仍存在潜在的细胞疗法开发挑战。在这篇综述中,讨论了与细胞治疗策略有关的当前细胞产品和专利技术。对该主题的详细讨论可能会为ALS细胞疗法的未来和可行性提供重要的见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号